Holen Sie sich die Stockscreener-App
48.09
1.03%
0.445
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$47.64
Offen:
$47.12
24-Stunden-Volumen:
7.82M
Relative Volume:
0.51
Marktkapitalisierung:
$212.87B
Einnahmen:
$50.91B
Nettoeinkommen (Verlust:
$18.95B
KGV:
11.28
EPS:
4.261
Netto-Cashflow:
$1.92B
1W Leistung:
+11.44%
1M Leistung:
+8.92%
6M Leistung:
-8.15%
1J Leistung:
-28.90%
1-Tages-Spanne:
$46.99
$48.50
1-Wochen-Bereich:
$43.90
$48.50
52-Wochen-Spanne:
$35.12
$71.80
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.09 | 209.88B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,204.16 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.57 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.15 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.98 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.03 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-18 | Eingeleitet | Bernstein | Outperform |
| 2026-03-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-03-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Herabstufung | Goldman | Buy → Neutral |
| 2026-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Kepler | Buy → Hold |
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Hochstufung | Jefferies | Underperform → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2025-12-08 | Herabstufung | Argus | Buy → Hold |
| 2025-10-27 | Fortgesetzt | Jefferies | Underperform |
| 2025-10-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-29 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-09-16 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Novo Nordisk consensus shifts after analyst moves, shares trade lower in Europe - Ad-hoc-news.de
NOVA Forecast — Price Target — Prediction for 2027 - TradingView
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B - TradingView
Novo Nordisk consensus after Morningstar downgrade, shares remain in focus on NYSE and Copenhagen - Ad-hoc-news.de
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? - The Motley Fool
Non-controlling/minority interest of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk (NYSE: NVO) repurchases 20,959,179 shares in 2026 - Stock Titan
Novo Nordisk updates analyst targets, shares stay in S&P 500 focus - Ad-hoc-news.de
Novo Nordisk wins key South Africa ruling, shares extend obesity-drug lead - Ad-hoc-news.de
Wegovy from Novo Nordisk A/ S (ADR)weekly injection reshapes obesity care - Ad-hoc-news.de
European ADRs Open The Week Higher In US Trading - Finimize
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk StockAnalyst consensus and GLP-1 momentum - Ad-hoc-news.de
Novo Nordisk (NYSE:NVO) Faces Cyber Breach While Pushing Oral Wegovy Into China - Sahm
Why Novo Nordisk’s Wegovy weekly injection changes daily routines - Ad-hoc-news.de
Why Novo Nordisk’s Ozempic FlexTouch pen keeps changing everyday routines - Ad-hoc-news.de
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models - Sahm
Novo Nordisk A/ S Stock (DK0062498333): China Wegovy filing puts the stock in focus - Ad-hoc-news.de
Novo Nordisk A/ S Stock (DK0062498333): Buyback Update Puts Capital Returns In Focus - Ad-hoc-news.de
Novo Nordisk (NVO) repurchases 19.9M B shares under 2026 plan - Stock Titan
Novo Nordisk A/ S Stock (DK0060534915): Technical picture draws investor focus - AD HOC NEWS
Novo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - Sahm
Novo Nordisk A/S Stock (DK0060534915): Wegovy tablet approval and ADRs in focus after late-week gain - Ad-hoc-news.de
Market news - investments.halifax.co.uk
Novo Nordisk Wegovy pill draws 10,000 UK waitlist ahead of approvalBloomberg - Investing.com Australia
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOD - TradingView
Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Share Weakness And GLP‑1 Growth Questions - simplywall.st
Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game' - Sahm
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows - Investing.com Nigeria
Novo Nordisk A/S stock (DK0062498333): Ozempic boom meets fresh obesity data and US pricing debate - AD HOC NEWS
European ADRs Started The Week In The Green - Finimize
Novo Nordisk ADR's decline widens rapidly to 3.8%, hitting a new intraday low - Bitget
Novo Nordisk stock falls on ADA conference readthrough - Investing.com
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle - Sahm
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk A/S stock (DK0062498333): Danish pharma heavyweight steadies after recent pullback - AD HOC NEWS
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):